BDR Pharmaceutical launched BDPARIB (RUCAPARIB) to treat advanced ovarian and prostate cancers today. BDPARIB is the first affordable generic in the India available in the form of a tablet, with the cost of therapy less expensive than
BDR Pharmaceutical launched BDPARIB (RUCAPARIB) to treat advanced ovarian and prostate cancers today. BDPARIB is the first affordable generic in the India available in the form of a tablet, with the cost of therapy less expensive than
Drug major on Thursday said it has received payment of USD 50 million (around Rs 363.5 crore) from Germany-based Boehringer Ingelheim for achievement of key milestones by its novel cancer drug, a potential target therapy for patients
Novartis announced robust data from the primary analysis of the pivotal phase II ELARA trial of Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL). Data will be presented as an oral presentation during
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM). The EC’s decision is based on results from the
Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Osimertinib tablets, used to treat lung cancer. The company has received tentative approval from the US Food and
The FDA’s crackdown on drugs that aren’t meeting approval requirements has now hit Roche. The Swiss pharmaceutical giant announced Monday that it is pulling its blockbuster drug Tecentriq from the U.S. as a bladder cancer treatment. The
Alkem Laboratories Limited has agreed to partner with Tata Memorial Centre (TMC) to establish an advanced Radiotherapy Facility as a part of the Homi Bhabha Cancer Hospital and Research Center, Muzaffarpur. As part of Alkem's CSR activity,
Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or
The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three
Merck, known as MSD outside the United States and Canada, and Eisai Inc. announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for applications seeking two new approvals for the combination
Recent Comments